SpePharm Initiates Legal Actions Against BioAlliance Pharma for Breaking Up Joint-Venture SpeBio
3/3/2009 10:44:49 AM
AMSTERDAM--(BUSINESS WIRE)--SpePharm Holding BV announces today that on February 11th 2009 the Company had initiated a summary proceeding before Dutch courts against BioAlliance Pharma of France. The summary proceeding seeksto prevent BioAlliance from breaking up their joint venture SpeBio. SpeBio BV was established in 2007 for the commercialization in Europe (excluding France) of Loramyc, a pharmaceutical product developed and registered by Bioalliance Pharma for the treatment of oropharyngeal candidiasis in immunocompromised patients. The District Court of Amsterdam had called both parties for a hearing on March 25th, 2009, with the objective to ask for normal business discussions to be resumed.